BioNTech SE (NASDAQ:BNTX) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. reduced its position in shares of BioNTech SE (NASDAQ:BNTX) by 8.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,736 shares of the company’s stock after selling 163 shares during the period. Advisors Asset Management Inc.’s holdings in BioNTech were worth $206,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after buying an additional 111 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the period. Blue Trust Inc. increased its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares in the last quarter. Gallacher Capital Management LLC lifted its stake in shares of BioNTech by 12.1% in the second quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock valued at $294,000 after purchasing an additional 395 shares during the period. Finally, TD Asset Management Inc boosted its holdings in BioNTech by 6.1% during the second quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock worth $612,000 after buying an additional 435 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Up 1.8 %

Shares of BNTX opened at $120.72 on Friday. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a fifty day moving average of $113.52 and a two-hundred day moving average of $98.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $28.94 billion, a PE ratio of -57.49 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the company earned $0.73 EPS. As a group, analysts forecast that BioNTech SE will post -3.68 EPS for the current year.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. JPMorgan Chase & Co. decreased their target price on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday. TD Cowen lowered their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. UBS Group lifted their price target on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Finally, Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.